Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
History[edit | edit source]
SPS was first described by Moersch and Woltman at the Mayo Clinic in 1956..
Symptoms and prognosis[edit | edit source]
Those with the illness experience progressive, fluctuating tonic muscle contractions, particularly the axial musculature. Depression and anxiety are often noted although this may be a result of discomfort due to stiffness, rather than underlying neurochemical abnormalities. MRI detection of GABA in the brain have demonstrated reduced levels in stiff-person syndrome.
Prognosis is variable and there is no reliable predictor of speed and severity of disease onset. Muscle tetany may lead to muscle rupture and broken bones, or problems swallowing and breathing in severe cases.
Postulated causes[edit | edit source]
Because many patients with SPS have circulating antibodies to the enzyme glutamic acid decarboxylase (GAD), an autoimmune cause of the disease has been postulated. However, GAD antibodies cannot be the sole cause, as most Type I diabetics possess anti-GAD antibodies, yet the frequency of SPS among Type I diabetics is 1 in 10,000. The GAD protein regions (epitopes) recognized by these antibodies may differ in each disease.. A mutation in GLRA1 (glycine receptor) is responsible for some cases of stiff person syndrome.
Treatment[edit | edit source]
In the absence of double-blind, placebo-controlled class A trials to determine treatment efficacy, some authorities recommend human trials of immunosuppressive therapy, plasmapheresis or intravenous immunoglobulin infusion. A recent study funded by the NINDS demonstrated the effectiveness of intravenous immunoglobulin (IVIg) treatment in reducing stiffness and lowering sensitivity to noise, touch, and stress in people with SPS.
References[edit | edit source]
- Moersch FP, Woltman HW (1956). Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases. Mayo Clin Proc 31 (15): 421–7.
- Hampe C, Hammerle L, Bekris L, Ortqvist E, Kockum I, Rolandsson O, Landin-Olsson M, Törn C, Persson B, Lernmark A (2000). Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J Clin Endocrinol Metab 85 (12): 4671–9. Cite error: Invalid
<ref>tag; name "Hampe" defined multiple times with different content
- eMedicine - Stiff Person Syndrome : Article by Nancy Rodgers-Neame
- Murinson BB (2004). Stiff-person syndrome. Neurologist 10 (3): 131–7.
- Levy L, Dalakas M, Floeter M (1999). The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 131 (7): 522–30.
- Hattan E, Angle MR, Chalk C (April 2008). Unexpected benefit of propofol in stiff-person syndrome. Neurology 70 (18): 1641–2.
See also[edit | edit source]
[edit | edit source]
- A site about the link between GAD and SPS at University of Birmingham Medical School
- stiffperson at NINDS
- Article at Cleveland Clinic
- Article at eNotes
- GAD antibodies at antibodypatterns.com
- Amphiphysin antibodies at antibodypatterns.com
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|